Zelda Therapeutics Limited announced that it has entered into an agreement with the National Health and Medical Research Council (NHMRC)-funded Australian Centre for Clinical Cannabinoid Research Excellence (ACRE), based at the University of Newcastle, to commercially supply a cannabis oil formulation, where prescribed, for participants in the Cannabinoids for Symptom Control in Advanced Cancer, An Open Label Prospective Clinical Trial in NSW (CARE NSW). The CARE NSW Clinical Trial is seeking to enrol up to 600 advanced cancer patients who will be prescribed a product selected from a range of cannabis medicines for symptom management. Zelda is one of several suppliers selected to supply investigation product for the trial under a commercial contract. The agreement does not guarantee suppliers with a minimum or maximum volume of the investigational product to be purchased nor the frequency of required supply to the CARE NSW trial.